Proskauer Reps Grifols In $3.4B Talecris Buy

Law360, New York (June 7, 2010, 5:18 PM EDT) -- Spanish health care company Grifols SA announced Monday that it had agreed to purchase Talecris Biotherapeutics for approximately $3.4 billion, nearly a year after a previous buyer for the Cerberus Capital Management LP dropped out under regulatory scrutiny.

The addition of Talecris' existing debt will bring the total price paid by Grifols to approximately $4 billion, Grifols said in the deal announcement.

Grifols is offering $19 — the same share price as Talecris' initial public offering announced in September — plus 0.641 nonvoting shares in Grifols...
To view the full article, register now.